InvestSMART

Atomo Diagnostics Limited (ASX:AT1)

ALERT: Price-sensitive ASX Announcement for AT1
Current share price for AT1 : $0.017 -0.01 (-37.04%)+
Announcement
Release
28 Apr 2026 9:53AM
Price at Release
$0.027
Full Release
download
Summary
Atomo Diagnostics Limited, trading on the ASX as AT1, has reported its financial and operational activities for the third quarter of the fiscal year 2026. The company, specializing in innovative diagnostics solutions, achieved a revenue of $814k for the quarter, enhancing its year-to-date revenue to approximately $3 million. Despite cash outflows of $2.6 million due to continued investment in program delivery and product supply, the company maintained a stable cash position of $2.6 million. Significant achievements included obtaining a US FDA CLIA waiver for Lumos’ FebriDx®, which opens up substantial growth opportunities in the US market. The quarter also saw new orders exceeding $2 million, primarily from HIV test sales, alongside strategic market expansion efforts.
Key Points
  • Atomo Diagnostics Limited reported for the quarter ending 31 March 2026.
  • The company operates in the diagnostics market, providing point-of-care testing solutions.
  • Revenue for Q3 FY26 was reported at $814k, contributing to a year-to-date total of approximately $3 million, a 4% increase compared to the previous year.
  • Significant cash receipts of $1.8 million were recorded, including $1.6 million from customers and $165,000 from a syphilis development grant.
  • Cash outflows for the quarter were $2.6 million, indicating ongoing investments in program delivery and product supply.
  • The company maintained a cash position of $2.6 million at the end of the quarter.
  • Atomo has secured a US FDA CLIA waiver for Lumos’ FebriDx®, enhancing growth potential in the US market.
  • New orders worth over $2 million were received during the quarter, including significant sales of HIV tests.
  • The company is expanding its market reach with new partnerships and customer acquisitions.
  • Staff and administrative costs remain a significant part of expenses, with notable payments to related parties.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.